Tacrolimus (FK506) is a macrolide lactone with potent immunosuppressive activity 100 times that of cyclosporine by weight. The molecular mechanism of action is mediated via an inhibition of the phosphorylase activity of calcineurin by drug-immunophilin complex, resulting in the inhibition of IL-2 gene expression. There are emerging studies now showing significant efficacy of tacrolimus in GVHD prevention in both related and unrelated donor transplantation. Three multicenter randomized studies comparing tacrolimus to cyclosporine have been completed, one each in related and unrelated donor transplantation; the remaining study involved both related and unrelated donor transplantation. All three studies showed a significantly lower incidence of grade II-IV acute GVHD in patients who received tacrolimus. One study in sibling donor transplantation showed that patients with advanced disease who received tacrolimus had a poorer survival than patients who received cyclosporine, but the survival was similar in patients with non-advanced disease. The remaining two studies, one in unrelated donors and the other combining both related and unrelated donors did not show any survival difference between the tacrolimus and cyclosporine groups. In addition, this review also highlights some of the critical questions regarding the role of this agent in allogeneic stem cell transplantation: (1) the contribution of methotrexate in combination with tacrolimus; (2) the starting i.v. dose of tacrolimus; (3) the suggested whole blood level of tacrolimus and its effect on nephrotoxicity; and (4) whether tacrolimus should be used in patients with advanced malignancy. Future studies using tacrolimus in combination with other immunosuppressants, and its use in patients with advanced malignancy will be warranted.
One of the challenges to reduce the morbidity and mortality after allogeneic bone marrow transplantation (BMT) is to improve the treatment and prevention of graft-versus-host disease (GVHD). 1 Currently, most regimens for GVHD prophylaxis are centered on cyclosporine as the main immunosuppressant given in conjunction with various doses and schedules of methotrexate and/or methylprednisolone. [2] [3] [4] [5] Most clinical trials suggested the superiority of a combination of cyclosporine and a short course of methotrexate over either agent alone. Yet, acute GVHD still developed in 9-33% of patients who received a marrow graft from an HLA-matched sibling donor. 3, 4, [6] [7] [8] [9] Tacrolimus is a new immunosuppressive agent introduced into clinical trials for the prevention of acute GVHD. Emerging results of these trials suggest that tacrolimus has significant clinical efficacy, perhaps surpassing cyclosporine for the prevention of acute GVHD. Nevertheless, toxicity associated with the use of tacrolimus can be substantial. This paper will review the pharmacology of this agent, its toxicity and the clinical outcome of acute GVHD prophylaxis.
Mechanism of action
Tacrolimus is a 23-membered macrolide lactone discovered in 1984 from the fermentation broth of a Japanese soil sample that contained the fungus Streptomyces tsukubaensis. 10, 11 Although tacrolimus has the molecular structure of a macrolide, it has limited antimicrobial activity. However, it has a potent inhibitory activity on T cell activation in both humans and mice. [12] [13] [14] [15] The in vitro activity of tacrolimus was 100 times that of cyclosporine with the inhibitory concentrations (IC 50 ) of 0.1 nmol/l and 10 nmol/l, respectively. 16 Clinically, tacrolimus has not only shown substantial efficacy in the rescue of liver graft rejection, 17 but also in the prevention of liver 18 , kidney [19] [20] [21] and cardiac graft rejection. 22, 23 Despite the structural differences between tacrolimus and cyclosporine, they share similar mechanisms of action at the molecular level. Both drugs mediate their activity through binding to an immunophilin. 24, 25 Tacrolimus binds to an immunophilin-FK binding protein-12 (FKBP12) to form an active tacrolimus-FKBP12 complex. This complex inhibits the phosphorylase activity of calcineurin, thus pre-venting the translocation of NFAT (nuclear factor of activated T cells) into the nucleus and resulting in an inhibition of IL-2 gene expression. Moreover, tacrolimus is capable of abrogating the conversion of precursor helper T lymphocytes to antigen-conditioned helper T lymphocytes in an in vivo model, whereas cyclosporine at 20-fold higher concentrations failed to exert this effect. 26 This differential effect may have important biologic consequences by abrogating the critical step of the immunologic cascade leading to organ rejection or graft-versus-host disease.
Pharmacokinetics

Absorption
The bioavailability of tacrolimus after oral administration in healthy volunteers varies from 14 to 17%. However, it is highly variable in solid organ transplant recipients, ranging from 4 to 89% with a mean of 25%. [27] [28] [29] [30] This variability in absorption is not well understood, but may be due to incomplete absorption resulting from poor solubility in gastric fluids, admixture with food, or changes in gut motility and metabolism. 30, 31 In liver transplant patients, food reduces the bioavailability of tacrolimus by 27 Ϯ 18.2% when compared to the fasting state. 30 Unlike cyclosporine, tacrolimus is not dependent on bile for absorption. The absorption of tacrolimus in orthotopic liver transplant recipients is similar regardless of the clamping of the Ttube. Therefore, dosage adjustments are unnecessary in patients with biliary obstructions. 28 A pharmacokinetic study was conducted between days 23 and 43 in 11 BMT recipients who received tacrolimus as a single agent for GVHD prophylaxis. 32 The whole blood concentration of tacrolimus peaked at 2.0 Ϯ 1.6 h with a bioavailability of 32 Ϯ 24%. The bioavailability of tacrolimus was modified by the concomitant administration of methotrexate and methylprednisolone. 33 The mean bioavailability of tacrolimus was significantly lower in the patients who received methotrexate (16 Ϯ 8%) when compared to patients who received either tacrolimus alone (49 Ϯ 10%) or tacrolimus in conjunction with methylprednisolone (27 Ϯ 12%). The decreased bioavailability in patients who received methotrexate was attributed to heightened radiation-induced gastroenteritis.
Distribution
Tacrolimus is highly bound to plasma proteins (75 to 99%) including alpha-1 acid glycoprotein, albumin, lipoproteins and globulins. 30, 34, 35 The drug rapidly distributes from plasma into the red blood cells. The high affinity of tacrolimus for red blood cells may be due to the high intracellular content of FKBP. 35, 36 Measurable concentrations of tacrolimus are present in the lungs, spleen, heart, kidney, pancreas, brain and liver. 27 Therefore, the volume of distribution (V d ) of tacrolimus in plasma and blood is large and variable, ranging from 0.85 to 65 l/kg. [29] [30] [31] 37 Because this variation is partly due to binding of tacrolimus to RBC, the V d determined by whole blood assay is lower than that determined by plasma concentrations. In BMT patients, the whole blood V d was 1.67 Ϯ 1.02 l/kg after a single intravenous dose of 0.02 mg/kg administered over 4 h. 32 
Metabolism and elimination
Tacrolimus is extensively metabolized by the mixed function oxidase system, primarily the cytochrome P450IIIa4 system in the liver, and possibly the small intestine. 27, [38] [39] [40] [41] Less than 1% of an intravenous or oral dose is found in the urine. 27, 42 The drug undergoes demethylation, hydroxylation and conjugation in the liver with most of the metabolites, and possibly conjugates, of tacrolimus eliminated in the bile. 27, 40, 43 Although many metabolites exist, their immunosuppressive activity is not well characterized. 27, 40, 44 Tacrolimus clearance determined by whole blood ELISA analysis was studied in 17 BMT patients on day 11 posttransplant. 33 These patients received either tacrolimus 0.03 mg/kg by continuous intravenous infusion alone or in combination with methylprednisolone or methotrexate. The clearances were 0.075 Ϯ 0.048, 0.055 Ϯ 0.023 and 0.063 Ϯ 0.032 l/h/kg, respectively, and these were not significantly different. Pharmacokinetics were also described in another 12 BMT patients who received intravenous bolus of 0.02 mg/kg over 4 h. 32 The half-life and clearance were 18.2 Ϯ 12.1 h and 0.071 Ϯ 0.034 l/h/kg, respectively.
Efficacy in bone marrow transplantation
The efficacy of prophylactic tacrolimus for GVHD in bone marrow transplantation was documented in two animal model systems. In the murine model, Blazar et al 45 demonstrated the reduction of mature T cell expansion in response to host alloantigens, resulting in a lower incidence of lethal GVHD. Tacrolimus also prevented the rejection of T celldepleted marrow allografts via a similar cellular mechanism. Using the canine model, long-term survival was found in five of 10 recipients of DLA-mismatched marrow and buffy coat when tacrolimus was given in conjunction with a short-course of methotrexate. 46 
Treatment of GVHD
Earlier reports on the use of tacrolimus in clinical bone marrow transplantation centered on the treatment of resistant acute and chronic GVHD, especially in patients who were resistant to steroids. In six children with steroid-resistant grade III-IV acute GVHD treated with tacrolimus, improvement was seen in the skin (6/6), gut (6/6) and liver (3/4). 47 In a Japanese study, 48 tacrolimus was given to 18 patients with acute GVHD unresponsive to cyclosporine or other immunosuppressants. Out of 13 evaluable patients with acute GVHD, seven responded. In the same report, 12 of 26 (46%) additional patients with chronic GVHD (seven with localized disease and 19 with extensive disease) responded to tacrolimus. The investigators at the University of Pittsburgh treated adult patients who had steroid-or cyclosporine-resistant GVHD (six acute and 24 chronic) and three patients who were intolerant to cyclosporine. 49 Twelve patients (36%) responded and survived with reduced steroid requirements. None of these studies were well controlled in terms of patient selection and response evaluation. Therefore it is difficult to define the role and efficacy of tacrolimus in the treatment of GVHD.
Prevention of GVHD
At present, there are 11 published studies evaluating the role of tacrolimus in the prophylaxis of acute GVHD in allogeneic transplantation. We have summarized the results of seven studies in related donor transplantation in Table 1 , and five studies in unrelated donor transplantation in Table 2 (one report included both related and unrelated donor transplantation 50 ). In the related donor transplant studies, five were singlecenter or limited institutional studies in patients with hematologic malignancies. 32, 33, [51] [52] [53] Collectively, there were 153 patients treated with tacrolimus and the incidence of grade II-IV acute GVHD was 15-44%. The other two studies were multicenter randomized trials comparing tacrolimus with cyclosporine. Both of these studies showed a significantly lower incidence of grade II-IV acute GVHD in patients randomized to the tacrolimus arm. In the North American trial, 54 the overall survival was worse in the tacrolimus arm. The poor survival in the tacrolimus arm was confined to patients with advanced disease (patients whose malignancies were not in remission or who had CML not in first chronic phase), whereas there was no survival difference between the two arms consisting of patients with nonadvanced disease (patients with CML in first chronic phase or whose malignancies were in remission). The other study Table 1 Transplants using related donor and tacrolimus for acute GVHD prophylaxis conducted by the Japanese FK506 BMT Study Group which included both advanced and non-advanced did not show a difference in survival. 50 In unrelated donor transplantation, there are three single institution studies [55] [56] [57] and two multicenter studies. 50, 58 The three single institution studies reported grade II-IV acute GVHD rates ranging from 34-50%. Two multicenter studies randomized patients to receive either tacrolimus or cyclosporine; one was conducted in North America and the other was conducted by the Japanese FK506 BMT Study Group. 50, 58 The North American study limited patient eligibility to those with non-advanced disease. The Japanese study included some patients with advanced disease. Both studies reported a lower rate of grade II-IV acute GVHD in patients randomized to the tacrolimus arm with no difference in survival.
Thus far, clinical trials have demonstrated substantial efficacy of tacrolimus for the prevention of acute GVHD, and also suggest the superiority of this agent over cyclosporine. These studies also raised several important practical questions. First, what was the contribution of methotrexate to the overall immunosuppressive activity of tacrolimus/ methotrexate? Most investigators favor the combination of tacrolimus and methotrexate, perhaps because of experience with cyclosporine/methotrexate which has proven to be superior to cyclosporine alone. Although two studies reported tacrolimus monotherapy to be effective in GVHD prophylaxis, there is no randomized study comparing tacrolimus/methotrexate to tacrolimus monotherapy. 32, 52 In contrast to cyclosporine, 2 the cumulative dose of metho- trexate may not correlate with the rate of acute GVHD. 51 Thus, it is possible that an attenuated dose of methotrexate may indeed preserve the immunosuppressive activity while minimizing the mucosal toxicity. This strategy has been used effectively in several studies which included both related and unrelated donor transplantation. 53, 56, 57 Second, what should be the starting dose of tacrolimus? The i.v. dose of tacrolimus employed in these studies ranged from 0.03 to 0.05 mg/kg/day. 32, 33, [50] [51] [52] [53] [54] [55] [56] [57] [58] Tacrolimus was administered by continuous infusion followed by oral administration at four times the intravenous dose when patients were able to tolerate oral intake. It is clear that even at a starting dose of 0.03 mg/kg/day, patients were unable to tolerate tacrolimus for more than several weeks because of nephrotoxicity. Przepiorka et al 56 reported a series of patients who received a starting dose of 0.03 mg/kg/day, the median last i.v. dose of tacrolimus was 53%, and the median oral dose at day 100 was 41% of the scheduled dose. This suggests that the starting i.v. dose of tacrolimus should not exceed 0.03 mg/kg/day and serum creatinine must be closely monitored. Third, should we adopt a tacrolimus whole blood level between 10-30 ng/ml as employed in many of these studies? An analysis to correlate the whole blood level of tacrolimus with the incidence of acute GVHD and nephrotoxicity has been reported. 59 There was no relationship between the whole blood level of tacrolimus and the rate of acute GVHD. On the other hand, nephrotoxicity significantly increased when the whole blood levels exceeded 20 ng/ml. This study suggests that the whole blood level of tacrolimus should be kept at 10-20 ng/ml. Fourth, can tacrolimus be used safely in patients with advanced malignancies? In the multicenter randomized study comparing tacrolimus with cyclosporine in sibling marrow transplant recipients, patients with advanced malignancy randomized to the tacrolimus arm had a significantly poorer survival compared to patients who received cyclosporine. The reason for the survival disadvantage in this subset of patients is unclear. Although several subsequent reports which included patients with advanced malignancy have reported excellent results, its use in patients with advanced malignancy should be cautioned.
Adverse effects
The major adverse effects associated with tacrolimus consist of nephrotoxicity, 32, 33, 51, 55, 60, 61 neurotoxicity, [62] [63] [64] [65] [66] [67] [68] hyperglycemia [69] [70] [71] [72] and hypertension. 73, 74 Other less prevalent adverse effects include infectious complications, [75] [76] [77] [78] [79] lymphoproliferative disorders, [80] [81] [82] [83] microangiopathic hemolytic anemia, 84 electrolyte abnormalities such as hyperkalemia, 85 hypomagnesemia, 86 and hypercholesterolemia. 36, 87 Unlike cyclosporine, tacrolimus rarely causes hirsutism, gingival hyperplasia, or coarsening of facial features.
88,89
The incidence of adverse events in stem cell transplant recipients is probably different from patients who had kidney or liver transplantation. This is due to the differences in dose schedule of tacrolimus employed in these clinical scenarios, concomitant use of other immunosuppressive agents, the presence of pre-existing organ dysfunction and toxicity from tumor-ablative regimens. Therefore, the pattern of adverse events seen in solid organ transplant recipients may not be applicable to bone marrow transplant patients.
Renal effects
Like cyclosporine, tacrolimus is a nephrotoxic agent. Several mechanisms of tacrolimus nephrotoxicity have been identified. Tacrolimus may lower the concentration of renin and aldosterone. 90 It also increases renal vascular resistance, reduces glomerular filtration rate and renal plasma flow, possibly by inducing the synthesis of endothelins which are renal vasoconstrictor peptides, 91, 92 and the vasoconstrictor thromboxane A2. 93 These mechanisms may act simultaneously in a given clinical situation. However, central to these physiologic derangements may be the binding of calcineurin in the kidney by the drug-immunophilin complex, which is shared by both cyclosporine and tacrolimus. 94 In several large clinical trials, nephrotoxicity was defined either as a doubling of serum creatinine to twice the baseline or as a serum creatinine Ͼ2.0 mg/dl. In these studies, the incidence of nephrotoxicity ranged from 32-92.6% in related donor transplants 32,33,51 and 63-88% in unrelated donor transplants.
55-57
TTP/HUS
Hemolytic uremic syndrome and thrombotic thrombocytopenic purpura during tacrolimus therapy has been reported following bone marrow transplantation. 95, 96 In contrast, tacrolimus has also been used as a successful alternative in patients with cyclosporine-induced hemolytic uremic syndrome.
97,98
Hyperglycemia
The diabetogenic effects of tacrolimus most likely result from the combined effects of inhibition of insulin secretion 99 and peripheral insulin resistance. 100 In one animal model, administration of tacrolimus at 10 mg/kg/day orally for 2 weeks caused a time-dependent suppression of insulin gene transcription in pancreatic beta cells due to inhibition of calcineurin. 101 Insulin mRNA transcription and insulin production returned to normal when the drug was discontinued, indicating that the adverse effect of tacrolimus on the pancreas is reversible. 101 Clinically, it is unclear whether the hyperglycemia associated with tacrolimus is dose-dependent. 72, 88 In a study using tacrolimus alone for GVHD prophylaxis, the incidence of hyperglycemia requiring treatment during the first 6 months was 41%. 32 Hyperglycemia requiring insulin treatment occurred in 5% of patients. 56 Many patients who developed GVHD were treated with corticosteroids, thus the additive effect of corticosteroids on hyperglycemia cannot be assessed. Other confounding factors may also contribute to hyperglycemia such as parenteral nutrition and pancreatitis.
Neurotoxicity
The clinical spectrum of neurotoxicity of cyclosporine and tacrolimus is very similar, ranging from mild symptoms of tremor and paresthesia to severe manifestations such as cortical blindness and seizures. 33, 47, 48, 68, [102] [103] [104] The similarities in the neurologic manifestations of these two agents, suggest a common mechanism of neurotoxicity, probably mediated through the interaction of drug-immunophilin complex with calcineurin. 105 Other neurological sideeffects in marrow transplant recipients include headaches, tremor, feeling of warmth, aphasia, flaccid paralysis, paresthesia of the extremities, insomnia, somnolence, rigidity of the limbs and nystagmus. 33, 47, 48, 55, 102 In one study, the incidence of severe headaches or burning paresthesia was 61% and some patients required narcotics for pain control. 33 These severe neurologic symptoms occurred while patients were receiving intravenous infusions and symptoms improved or resolved after decreasing the infusion rate or switching to the oral route. Reversible cerebral blindness and posterior leukoencephalopathy were also reported with both cyclosporine and tacrolimus. 68, 103 Factors that may be associated with neurotoxicity are hypocholesterolemia, hypertension, hypomagnesemia, nephrotoxicity and high blood levels of tacrolimus.
68,106-109
Hypertension
Several factors contribute to the development of hypertension seen with the administration of tacrolimus. These factors include intrinsic renal damage caused by the drug, increased vasomotor tone, increased intravascular volume and concomitant use of corticosteroids. 110, 111 Hypertension requiring treatment ranged between 21-63% in related and unrelated donor transplants. 32, 33, 51, 55, 56 The wide range seen in these studies may be due to the many confounding variables such as steroids which contribute to the incidence of hypertension.
Drug interactions
Tacrolimus has been shown to act as an inhibitor of cytochrome-P450 drug metabolism, making many drug interactions possible. [112] [113] [114] Most of the drug interactions postulated have been based on in vitro data and little information exists from human trials. [115] [116] [117] There is a high likelihood of drug interaction between tacrolimus and other agents administered concomitantly. Drug interactions with tacrolimus that are known to occur or for which a strong possibility for interaction exists are listed in Table 3 . Agents known to induce or inhibit the P450 enzyme system should be administered with caution to patients receiving tacrol- Table 3 Potential drug interactions with tacrolimus 27, 30, 115, 116, [120] [121] [122] [123] [124] [125] [126] [127] [128] [129] Drugs that may increase tacrolimus concentrations Cimetidine a,g Pharmacokinetic studies in BMT patients who received tacrolimus alone or in combination with methylprednisolone or methotrexate showed no difference in clearance of tacrolimus. 33 On the other hand, there was a concern regarding the potential of delayed clearance of methotrexate by tacrolimus via mechanisms similar to another macrolidelike compound, pristinamycin. 118 This issue was addressed in a study of 80 BMT recipients participating in a randomized study comparing tacrolimus/methotrexate and cyclosporine/methotrexate. This study did not find a significant alteration in methotrexate clearance by tacrolimus. 119 Fluconazole is another common agent given concomitantly with tacrolimus. Osowski et al 120 investigated the interaction between daily intravenous fluconazole dose of 400 mg/kg and cyclosporine or tacrolimus in allogeneic BMT patients. They reported that the clearances of cyclosporine and tacrolimus were reduced by 21% and 16%, respectively. The authors felt that the alterations of tacrolimus clearance were not clinically significant. However, concomitant administration of fluconazole and tacrolimus in solid organ transplant recipients had resulted in acute renal toxicity. 121, 122 The difference might have been that solid organ transplant recipients received a higher dose of tacrolimus. The potential drug interaction of tacrolimus underscores the needs for vigilant monitoring of the blood levels in BMT patients, whose clinical complexity often demands the concomitant use of multiple pharmacologic agents.
Conclusion
Tacrolimus is a new macrolide immunosuppressant with a mechanism of action similar to that of cyclosporine. Tacrolimus has been shown to be effective in the prevention of acute GVHD. Common adverse effects of tacrolimus, like cyclosporine, are nephrotoxicity, neurotoxicity, hyperglycemia and hypertension. However, tacrolimus rarely causes hirsutism or gingival hyperplasia. Three large randomized trials have been completed, comparing tacrolimus to cyclosporine for the prevention of GVHD in matched sibling donor transplantation and matched unrelated donor transplantation. 50, 54, 58 All three trials showed the superiority of tacrolimus over cyclosporine in the prevention of grade II-IV acute GVHD. In the trials which included only non-advanced malignancies, the survivals were similar. Several single institution trials of tacrolimus, which include many patients with advanced disease both in sibling and unrelated donor transplantation, have reported excellent survivals. 32, 33, 51, 52, 56, 57 The clinical application of tacrolimus for the treatment and prevention of GVHD will continue to evolve. Future studies of this agent in combination with other immunosuppressants for GVHD prevention may further improve the outcome of allogeneic bone marrow recipients.
